Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism CDC42 inhibitors(Cell division control protein 42 homolog inhibitors), RAC1 inhibitors(Rac family small GTPase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H18N4 |
InChIKeyLJCANTASZGYJLG-UHFFFAOYSA-N |
CAS Registry2097938-73-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 1 | United States | 09 Nov 2023 | |
Advanced breast cancer | Phase 1 | Puerto Rico | 09 Nov 2023 | |
Neoplasms | Preclinical | Hungary | 28 Apr 2025 | |
Breast Cancer | Preclinical | - | - |
Not Applicable | - | fcutiudrlx(spdjzcyzan) = PXL treatment increased metastasis to the lungs and liver, while MBQ-167 prevented lung and liver metastases and reduced PXL-induced metastasis cuimvbklgi (lzrbinugyk ) View more | - | 01 Mar 2023 |